Introduction {#s1}
============

Since the discovery in 2005 of the clinical utility of Temozolomide in glioblastoma (GBM) patients ([@B1]), no other cytotoxic drug was added in the standard treatment protocols. In the meantime our knowledge on the molecular mechanisms deranged in GBM has had impressive advancements and the possibility of targeting these pathways has been extensively exploited in the hope to improve the current standard of care ([@B2]--[@B4]). Differently from many other tumors, in GBM the promises of molecularly targeted therapies against oncogenic alterations did not meet success in phase I/II and III trials even though they were highly promising in preclinical models; thereafter they have limited clinical utilization ([@B5]). The lack of success of targeted therapies and the limited activity of standard cytotoxic treatments in GBM, reside in the cellular complexity and clonal evolution of this tumor ([@B6], [@B7]). Moreover, many molecules that display strong antitumor activity *in vitro* against glioma cells and that are utilized for the therapy of other tumors, are ineffective *in vivo* because they cannot pass through the Blood Brain Barrier (BBB), or because of drug efflux, intrinsic or rapidly developing drug resistance and, last but not least, the presence of a pool of cancer cells with stemness characteristics ([@B7]).

In the recent years, targeting the so-called Immune Checkpoint molecules (ICs) which provide inhibitory signals to T cells, has offered new exciting treatment opportunities in cancer ([@B8]). Inhibition of autoreactive CD8^+^ T-cells through ICs is a physiological mechanism to prevent autoimmunity; on the other end, this mechanism inhibits the immune response against aberrant cancer cells. Differently from conventional cytotoxic or from targeted therapies that are aimed at the cancer cells, the therapies that involve the modulation of ICs attempt to redirect the function of the immune system to elicit cancer cell death. Several checkpoint molecules capable to shut down the response against neo-antigens are present on T cells as well as on tumor cells. These molecules are at the center of regulatory networks that result in immunosuppression. Antibodies against the "classic" IC molecules (CTLA-4, PD-1, PD-L1, and PD-L2) are considered the "first generation" IC inhibitors (ICis) that interfere with the immune escape of tumor cells, followed by second and third generations ICis targeting other immunoregulatory molecules and pathways ([@B9], [@B10]).

Immune checkpoints inhibition dramatically improved survival in hard-to-treat tumors like lung cancer and melanoma so that the therapy with IC inhibitors (ICis) has entered in the standard clinical practice for these tumors whereas clinical trials have been launched for many other tumors ([@B8], [@B10]).

Blood-brain barrier, immunological mechanisms and immune checkpoints interplay in glioblastoma {#s2}
==============================================================================================

For many years the CNS has been considered as an immune-privileged compartment with the BBB responsible to maintain a constant brain microenvironment from metabolic insults and, at the same time, physically blocking or actively favoring the transport of bioactive molecules. During the development of glioma, the integrity of the BBB is preserved up to a tumor size of \~2 mm^3^; above that, the angiogenetic pressure elicited by GBM releases the tight and adherent junctions between the cerebral endothelial cells allowing the passage of molecules up to 12 nm ([@B11], [@B12]). With further tumor growth the BBB becomes freely permeable to larger molecules. Nevertheless, tumor cells in niches at the boundary of the surgically excised tumor remain protected by the BBB reducing the efficacy of the treatment. Beside immune cells ([@B13]), several cell types in the brain (microglia, astrocytes) can act as antigen-presenting cells and elicit immune response against the tumor. This mechanism is aided by the permeability of the damaged BBB that enables the passage of tumor antigens outside the brain ([@B14]--[@B16]). Similarly to other tumors, GBM is associated with significant immunosuppression particularly in the T-cell compartment ([@B17]) because of the combined effect of steroid/cytotoxic treatment, the downregulation of MHC-I antigens and of the secretion of immunosuppressive cytokines. Moreover, also in glioma, the correct maintenance of the physiological status of immunological tolerance and response is mediated by the coordinate interplay of many actors, including IC molecules, and different cell types as summarized below and in Figure [1](#F1){ref-type="fig"}.

![Simplified representation of the IC network. In red are indicated the FDA-approved drugs and the IDO inhibitors in advanced stage of clinical test (phase III). TIM-3 inhibitors are at an early stage of development for clinical use (phase I).](fonc-08-00464-g0001){#F1}

CTLA-4
------

CTLA-4 (CD152) was the first immunoregulatory molecule to be targeted for therapeutic purposes utilizing the humanized antibody Ipilimumab approved by FDA and EMA in 2011, initially for melanoma ([@B18]), soon followed by Tremelimumab for mesothelioma ([@B19], [@B20]). CTLA-4, expressed on T-cells (activated and regulatory), interacts with its ligands CD80 and CD86 on APCs to inhibit co-stimulators T-cell pathways ([@B21]). In GB the expression of CTLA-4 on CD4^+^ and CD8^+^ cells is strongly inversely correlated with outcome ([@B22]).

PD-1/PD-L1
----------

PD-1 on T cells and its ligand PD-L1 on APC and tumor cells are the most important immunosuppressive molecules so far identified. Their interaction leads to the suppression of early T-cell activation, abolishing their cytotoxic activity and interferes with the production of inflammatory cytokines ([@B23], [@B24]). Two PD-1 suppressive Ab were licensed in 2014 (Nivolumab) and in 2016 (Pembrolizumab) and two anti-PD-L1 Ab: Atezolizumab in 2016 and Avelumab in 2017. Their original indications were rapidly extended to other tumors and many clinical trials with newer molecules are ongoing ([@B8], [@B25], [@B26]). The expression of PD-L1 on glioma cells has been documented as well as that of PD-1 on tumor infiltrating lymphocytes (TIL). The functional and clinical implications of PD-1/PD-L1 expression in GBM are still unclear. Indeed, no correlation between PD-L1 expression and overall survival was seen in two cohorts ([@B27], [@B28]). On the other hand, in another study, PD-L1 staining and PD-1/PD-L1 expression were associated with decreased survival ([@B29]). The absence of standardized experimental parameters, of defined cut-off values and the heterogeneity of the cohorts might explain these contrasting findings. Interestingly PD-L1 expression is directly correlated with WHO grade and within Grade IV tumors, PD-L1 expression is significantly higher in IDH1/2 wt tumors compared to IDH1/2 mutated or hyper methylated GBM ([@B27]). Overall, the expression of PD-L1 is linked to well-known negative prognostic indicators in GBM and its effect on survival must be examined in homogeneous cohorts.

Tim-3
-----

Tim 3 is a molecule expressed by CD4+ and CD8+ T cells that, similarly to PD-1, is involved in immune suppression and promotes tumor escape through the exhaustion of T cells ([@B30]). A large proportion of TILs in GBM and other tumors is composed by T cells not capable of cytokine secretion and not exerting their physiological function. In GBM the overexpression of TIM-3 is associated with higher malignancy (higher grade, lower Karnofsky score, and IDHwt) and is thus considered a strong negative prognostic indicator ([@B31], [@B32]).

IDO
---

Although IDO is not a classical immune checkpoint molecule and lacks receptorial capacity, it is included in this functional class because of its suppressive properties on T-cell activation and NK cell function ([@B33]). Similarly to TIM-3, IDO overexpression is linked to poorer outcome in GBM patients ([@B34]) and targeting IDO with Epacadostat or Indoximod ([@B35]), was a successful experimental strategy in *in vivo* models ([@B36]).

Genetic and epigenetic factors determine the functionality of IC molecules {#s3}
==========================================================================

Targeting IC molecules with blocking antibodies alone or in combination with other ICi therapies, or with standard chemotherapy has revolutionized the therapeutic approach to lung cancer and other hard to treat tumors. Nevertheless, along with very favorable response rate, other patients are unresponsive to the therapy or show life-threatening side effects. Predicting the response and the appearance of major side effects during treatment is a major health issue. Limiting certain therapies to patients likely to respond and strict monitoring of patients at risk have several ethical implications and could enable the Public Health Systems to offer the best available therapy to the patients who could really benefit from it. However, reliable biomarkers predicting response or adverse reactions to ICi therapy are not yet available.

Single nucleotide variations (SNVs) of IC genes can affect the expression levels of IC molecules thus altering immune tolerance and leading to increased susceptibility to autoimmune diseases or to reduced immunological response against cancer cells.

A meta-analysis that included 12 studies and more than 5,000 tumor patients and an equal number of healthy controls showed a decreased cancer risk for TT homozygous individuals at polymorphism PD-1.5 (rs2227981) and, for Asian populations, a decreased risk was seen for AG individuals and an increased risk for AA, at PD-1.3 (rs11568821) ([@B37]). PD-1.5 allele frequencies and risk of low- and high-grade glioma development were examined in 156 mid-Eastern patients and significantly higher frequency of the PD1.5 C/T and T/T genotype were found in high-grade glioma compared to low-grade tumors and control individuals ([@B38]).

Some studies, described below, have examined the clinical impact of IC polymorphisms in tumor and autoimmune disease patients treated with ICi. Years ago, it was shown that SNVs in *CTLA-4* may affect the transcriptional activity of the gene as well as the interaction with CD80 and influence immune response in autoimmune diseases ([@B39], [@B40]). SNV of *CTLA-*4 are implicated in clinical response and survival in melanoma patients ([@B41], [@B42]) and, more recently, SNV-1577G \> A and SNV CT60G \> A were linked to a better response to Ipilimumab in a 173-patients cohort ([@B43]) and SNV-1661A \> G to the onset of endocrine adverse events ([@B44]).

In NSCLC *CTLA*-*4, PD*-*1*, and *PD*-*L1* were examined in two studies that involved more than 400 patients ([@B21], [@B45]). Overall three *PD*-*L1* SNV (rs2282055G \> T; rs4143815C \> G, and rs2297136T \> C) were significantly associated with a better overall response rate and improved OS and PFS when treated with chemotherapy alone or with Nivolumab as second or third line of treatment after chemotherapy.

Overall these results indicate that genetic variations in IC molecules can be utilized as conventional biomarkers predictive of response to treatment and outcome to optimize patients\' treatment. This is particularly important also in view of the availability of new drugs whose efficacy and toxicity may be genetically-dependent and whose utilization requires a "personalized approach" to cancer treatment.

Studies on hematologic disorders like myelodysplastic syndrome (MDS) treated with inhibitors of DNA methyltransferases demonstrated the up-regulation of PD-1 as a consequence of the therapy ([@B46], [@B47]). High expression of PD-1 is a negative prognostic indicator and it has been proposed that the treatment of MDS with hypomethylating agents should be coupled with the blockade of ICs.

The analysis of several solid tumors demonstrated that epigenetic mechanisms regulate the expression of IC molecules and that methylation of PD-1 and PD-L1 promoters is associated with worse outcome ([@B48]--[@B51]).

The immunological landscape of glioma is influenced by IDH1/2 mutations; indeed, in mutated tumors PD-L1 is significantly diminished supporting the rationale of ICi treatment in IDH1/2wt patients ([@B52]). Besides DNA methylation, other epigenetic modifiers may influence IC expression in glioma. Namely, miRNAs may directly impact CTLA-4, PD-1, and PD-L1 expression through a series of miRNA like mir-155 (CTLA-4), mir-138 (CTLA-4 and PD-1), miR-424 (PD-L1 and CD80), mir-28 (PD-1), miR-34a, miR-200 miR-513, and miR-138-5p (PD-L1).

Moreover, the same or other miRNA regulate the expression of cytokines like IFN-γ or transcription factors that are positive or negative regulators of IC generating a redundant and extremely complex network. The interaction between IC molecules, and miRNA have been recently shortly reviewed ([@B53]).

Immune checkpoint blockade in GBM: preclinical findings {#s4}
=======================================================

Several preclinical trials conducted utilizing two immunocompetent animal models (GL261/C57Bl/6 and SMA560/VM/dk) ([@B54]) demonstrated that IC blockade utilizing ICi as single agent or in combination significantly prolongs survival at an extent that depends on the molecule, or their combination. In one study, CTLA-4 blockade alone resulted in 80% of long survivors ([@B55]) whereas in two others the percentage of long survivors was 40 and 25% ([@B28], [@B56]). PD-1 blockade alone resulted in 56% long survivors in one study ([@B57]) but had no effect in another study unless associated with radiotherapy (15--40% long survivors) ([@B58]). PD-L1 blockade was tested in two studies leading to 60% ([@B57]) and 25% long survivors ([@B56]). Only one study examined the effect of TIM-3 blockade with no effect on survival ([@B59]). The effect of the therapy was strongly augmented when different ICis were utilized in combination or with standard therapy. Two studies in murine models demonstrated that the combination of radiation therapy and PD-1 and/or TIM-3 exerted a strong antitumor response over the treatment with a single agent and the maximal activity (100% long survivors) was seen when PD-1 and TIM-3 inhibition were combined with stereotactic radiosurgery ([@B58], [@B59]). Another study described the effects of the concomitant CTLA-4/PD-L1/PD-L2 inhibition that resulted in 75% long survival ([@B56]). Finally, disabling the entire IC network (CTLA-4/PD-L1/IDO) ([@B57]) or the dual IC blockade (TIM-3/PD-1) coupled with radiosurgery ([@B59]), both resulted in the survival of 100% of the treated mice. Importantly in all these treatments it was possible to demonstrate the activation of the immune system within the tumor (cytokines production, TIL activation, etc.) and sustained anti-tumor immune response since regrowth of the tumor was not observed after tumor cell re-challenge.

Overall, these preclinical models support the rationale for disabling many components of the IC network in conjunction with standard therapies for an efficient glioma treatment. Moreover, since the concomitant utilization of several ICis could increase the risk of life threatening adverse effects, the need of identifying molecular markers predicting response and therapy-induced toxicity, as previously mentioned, appears of the utmost importance for the clinical utilization of combined IC treatment.

Immune checkpoint blockade in GBM: clinical trials {#s5}
==================================================

The successful preclinical trials and the very favorable results obtained with other tumors like NSCLC and melanoma, set the basis for the utilization of ICis in many other tumors including GBM. The survey of the NIH Clinical Trials Database (<https://www.clinicaltrials.gov>) performed on July 2018, showed 60 registered trials; only two of them were completed (Table [1](#T1){ref-type="table"}). One of the completed studies (NCT01860638) is a phase II randomized study to test the safety of the combination Bevacizumab/Lomustine as second line treatment followed by Nivolumab as third line. The primary endpoint of the study that enrolled 296 patients and ended in 2017 was OS but the results were not made available to the public. The second completed study was NCT02550249, a phase II study that enrolled 29 patients and had as primary outcome the evaluation of the expression of PD-L1 in tumor cells and lymphocytes upon treatment with Nivolumab. Also, in this case the results are not available.

###### 

Clinical trials with IC inhibitors in glioma (July, 2018).

  **Target**       **Clin. Trial ID**   **Molecule**                                                                                **Disease**                          **Phase**   **Patients**   **Status**                      **Year S/E**
  ---------------- -------------------- ------------------------------------------------------------------------------------------- ------------------------------------ ----------- -------------- ------------------------------- --------------
  CTLA-4           NCT03460782          Ipilimumab                                                                                  Glioblastoma                         I           ?              ?                               2018/?
  PD-1 + CTLA-4    NCT03430791          Nivolumab + Ipilimumab                                                                      Glioblastoma                         II          60             Not yet recruiting              2018/2021
                   NCT03233152          Ipilimumab + Nivolumab                                                                      Glioblastoma                         I           6              R                               2016/2019
                   NCT02017717          Ipilimumab + Nivolumab + Bevacizumab                                                        Glioblastoma                         III         626            A-NR Data available (Ref. 59)   2013/2018
                   NCT03367715          Ipilimumab + Nivolumab                                                                      Glioblastoma *MGMT* Unmeth           II          24             R                               2018/2020
                   NCT02311920          Ipilimumab + Nivolumab + TMZ                                                                Glioblastoma Gliosarcoma             I           32             A-NR                            2015/2018
                   NCT03425292          Ipilimumab + Nivolumab + TMZ                                                                Glioblastoma                         I           45             R                               2018/2020
                   NCT03422094          Ipilimumab + Nivolumab + personalized vaccine (NeoVax)                                      Glioblastoma                         I           30             Not yet recruiting              2018/2023
  CTLA-4 + PD-L1   NCT02794883          Tremelimumab + Durvalumab                                                                   Glioblastoma                         II          36             R                               2016/2019
  PD-1             NCT01952769          Pidilizumab                                                                                 DPIG                                 I/II        50             A-NR                            2014/2019
                   NCT02359565          Pembrolizumab                                                                               DPIG and other brain tumors          I           110            R                               2015/2020
                   NCT02529072          Nivolumab + Dendritic cell vaccine                                                          Glioblastoma                         I           7              A-NR                            2015/2017
                   NCT03576612          Nivolumab + immunostimulator                                                                Glioblastoma                         I           36             A-NR                            2018/2022
                   NCT03557359          Nivolumab                                                                                   IDHmut GB                            II          37             A-NR                            2018/2021
                   NCT03347097          PD-1 producing pluripotent killer cells                                                     Glioblastoma                         I           40             R                               2017/2018
                   NCT02311582          Pembrolizumab + laser ablation                                                              Glioma                               I/II        58             R                               2015/2021
                   NCT02658981          Nivolumab + anti-LAG-3                                                                      Glioblastoma                         I           100            R                               2016/2020
                   NCT02852655          Pembrolizumab                                                                               Glioblastoma                         NA          35             A-NR                            2016/2021
                   NCT02335918          Nivolumab + Varilumab                                                                       Glioblastoma solid tumors            I/II        175            A-NR                            2015/2020
                   NCT02526017          Cabiralizumab + Nivolumab                                                                   Glioblastoma solid tumors            I           295            A-NR                            2015/2019
                   NCT03058289          INT230-6 (cytotoxic carrier, intratumor) + Nivolumab                                        Glioblastoma solid tumors            I/II        60             R                               2017/2020
                   NCT01860638          Bevacizumab + Lomustine + Nivolumab + TMZ + Radiotherapy                                    Glioblastoma                         III         296            C - No results available        2013/2017
                   NCT03014804          Dendridic cell vaccine + Nivolumab                                                          Glioblastoma                         II          30             To be started                   2018/2020
                   NCT03493932          Nivolumab + Anti-LAG-3                                                                      Glioblastoma                         I           15             R                               2018/2021
                   NCT02798406          Oncolytic Adenovirus (intratumor) + Nivolumab                                               Nervous System Tumors                II          48             R                               2016/2020
                   NCT02937844          Chimeric T cells armed with PD-1 and CD28 to activate T cells and kill PD-L1+ tumor cells   Glioblastoma                         I           20             R                               2016/2019
                   NCT03173950          Nivolumab                                                                                   Brain tumors not GB                  II          180            R                               2017/2021
                   NCT03170141          CAR-T cells                                                                                 Glioblastoma                         I           20             R by invitation                 2017/2020
                   NCT03491683          Cemiplimab + immunomodulators INO-5401 and INO-9012                                         Glioblastoma                         I/II        52             R                               2018/2021
                   NCT02829931          Nivolumab + radiotherapy                                                                    Glioblastoma                         I           26             S by the Company                2016/2020
                   NCT02550249          Nivolumab                                                                                   Glioblastoma                         II          29             C - No results available        2015/2017
                   NCT02648633          Nivolumab + Valproic Acid                                                                   Glioblastoma                         I                          WT                              2016/2017
                   NCT03452579          Nivolumab + Bevacizumab                                                                     Glioblastoma                         II          90             R                               2018/2018
                   NCT02667587          Nivolumab + TMZ + radiotherapy                                                              Glioblastoma                         III         693            R                               2026/2023
                   NCT02617589          Nivolumab + TMZ + radiotherapy                                                              Glioblastoma                         III         550            R                               2016/2019
                   NCT03311542          Pembrolizumab                                                                               Glioblastoma Melanoma                ?           ?              ?                               2017/?
                   NCT02313272          Pembrolizumab + Bevacizumab + radiotherapy                                                  Glioblastoma                         I           32             A-NR Data Available (Ref: 62)   2015/2019
                   NCT02054806          Pembrolizumab                                                                               Glioblastoma and many solid tumors   I           477 (26 GB)    A-NR Data Available (Ref: 61)   2014/2018
  PD1 + IDO        NCT03491683          Epacadostat + Nivolumab                                                                     Glioblastoma                         I/II        52             R                               2018/2021
  PD-L1            NCT02968940          Avelumab + radiotherapy                                                                     Glioblastoma IDHmut                  II          43             R                               2017/2019
                   NCT03291314          Avelumab + Axitinib                                                                         Glioblastoma                         II          52             R                               2017/2018
                   NCT02866747          Durvalumab + radiotherapy                                                                   Glioblastoma                         I/II        62             R                               2017/2020
                   NCT03341806          Avelumab + lasertherapy                                                                     Glioblastoma                         I           30             R                               2018/2020
                   NCT02336165          Durvalumab + radiotherapy + Bevacizumab                                                     Glioblastoma                         II          159            A-NR Data Available (Ref:63)    2015/2018
                   NCT03047473          Avelumab                                                                                    Glioblastoma                         II          30             R                               2017/2019
                   NCT03174197          Atezolizumab + TMZ                                                                          Glioblastoma                         I/II        60             R                               2017/2021
                   NCT03158389          Atezolizumab + targeted therapy with various molecules                                      Glioblastoma                         I/II        350            R                               2018/2024
  IDO              NCT02052648          Indoximod + radiotherapy + TMZ + Bevacizumab                                                Glioblastoma                         I/II        160            A-NR                            2014/2018
                   NCT02502708          Indoximod + TMZ + radiotherapy + other cytotoxic drugs                                      Pediatric brain tumors               I           115            R                               2015/2019
                   NCT02764151          PF-06840003                                                                                 Brain tumors                         I           17             A-NR                            2016/2018

Data taken from <https://www.clinicaltrials.gov>

*R, Recruiting; C, Completed; A-NR, Active Not Recruiting; AC, Accrual completed; NI, Not Indicated; WT, Withdrawn; S, Suspended; Year S/E, Year Start/End*.

The ongoing studies (mostly phase I or II) test several ICi molecules as single agents or in various combinations with standard cytotoxic molecules, targeted therapies, or other immunological therapies and are aimed, not only at determining the clinical utility of these molecules, but also at determining the safety of the treatment and are expected to be completed starting from 2019 but mostly after year 2020.

The only study with published results is NCT02017717 (CheckMate 143), a large phase III randomized trial that enrolled over 600 patients. This study was the first large trial where the effect of IC inhibitors was stringently tested. Encouraging results were initially obtained in one of the study arms where three patients showed partial response and 8 disease stabilization with the combination Nivolumab+Ipilimumab ([@B60]), however when the study was extended, this arm was closed because of the treatment failure ([@B61]).

Two other large phase III randomized trials (NCT02617589 and NCT02667587) are testing the effect of Nivolumab on MGMT methylated or unmethylated patients and the results of these studies are expected in 2019 and 2023, respectively.

Phase Ib trial NCT02054806 tested the safety and efficacy of the PD-1 inhibitor Pembrolizumab on a large series of solid tumors. In the GBM arm (26 patients), one partial response and 12 disease stabilization were observed ([@B62]).

Phase I trial NCT02313272 tested the effect of the addition of Pembrolizumab to Bevacizumab and radiotherapy. The initial results were encouraging since more than 50% of the patients at 6 months showed partial or complete response ([@B63]).

Finally, phase 2 trial NCT02336165, the PD-1 inhibitor Durvalumab was tested in combination with Bevacizumab and radiotherapy and showed partial response or disease stabilization in 60% of the patients after 6 months. Four patients remained progression free ([@B64]).

Conclusions {#s6}
===========

Targeting ICs has revolutionized the therapeutic approach to certain tumors. There is strong hope that this therapy could be effective also for GBM patients. Indeed, the preclinical trials and the initial results obtained in some phase I/II studies suggested that ICis could offer new therapeutic options to these patients. The results of the first large phase III trials were somehow disappointing and inhibiting PD-1 could not fully restore the host immune response ([@B61]).

Nevertheless, the treatment with Nivolumab doubled the response to therapy in 8% of the patients (11.1 months vs. 5.3 with Bevacizumab) ([@B61]). Moreover, the high levels of VEGF seen in GBM are strongly immunosuppressive and this effect should be better counteracted. In this respect, targeting multiple IC pathways also in combination with cytotoxic drugs could be a winning strategy. The results of the two ongoing phase III trials and of the phase I/II trials where combination therapies are explored may provide new weapons against this rapidly and invariably deadly cancer.

Author contributions {#s7}
====================

MR conceived the idea of this mini-review article and wrote the first draft. BB, MP, RC, AM, and MR equally participated to the final writing of the article.

Conflict of interest statement
------------------------------

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This study was supported by the Italian Ministry of Health, Core Grant Ricerca Corrente to the IRCCS Ospedale Policlinico San Martino, Genova, by the grant from the Fondazione Compagnia di San Paolo--Torino: Terapie innovative per il glioblastoma and by the grant Associazione Italiana Ricerca sul Cancro (AIRC) 5 × 1000 N. 21073 Epigenetic modeling/remodeling of cancer metastases and tumor immune contexture to improve efficacy of immunotherapy.

[^1]: Edited by: Shiv K. Gupta, Mayo Clinic, United States

[^2]: Reviewed by: Karishma Rajani, Mayo Clinic, United States; Sujuan Guo, Dana--Farber Cancer Institute, United States

[^3]: This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
